A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Talazoparib (Primary)
- Indications Malignant-mesothelioma; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TALAMESO
- 28 Jan 2021 Status changed from not yet recruiting to recruiting.
- 09 Jul 2020 New trial record